Patients bring adipose banking into gynecology visits after seeing it advertised, and the questions rarely start with the biology. This OB-GYN adipose banking guide works through the questions that actually arrive in the exam room and gives a defensible answer to each. The framing throughout is storage and regulation, because that is where the verified ground sits.
TLDR: Adipose tissue is an endocrine organ, which is why women’s health patients assume a hormonal connection and why these questions land in this specialty. That biology establishes nothing about what stored cells could do. No adipose-derived product is FDA approved for any gynecologic indication. The federal analysis runs through the four criteria at 21 CFR 1271.10(a), which separate a 361 tissue product from a 351 biological drug, and Florida authorizes non-FDA-approved stem cell therapy only for orthopedics, wound care, and pain management, so gynecologic use falls outside it. Banking is storage, and it does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat is a connector linking patients and providers to a United States tissue bank. Save My Fat does not provide FDA-approved treatments or cures and does not guarantee eligibility, access, or clinical benefit. No adipose-derived product is FDA approved for any gynecologic, reproductive, or hormonal indication, and nothing here should be read as suggesting otherwise. This article is written for licensed clinicians for educational purposes only and is not legal advice, and patients should consult their own licensed healthcare professionals before making any decision about banking.
The question usually arrives sideways. A patient mentions a clinic she found online, or an ad she was served, and asks whether she should be storing fat while she still can. She is not asking about the Code of Federal Regulations. She is asking whether her physician thinks it is worth doing.
Adipose banking reaches women’s health physicians through advertising far more often than through the literature. The clinician is not evaluating a therapy. She is correcting assumptions the patient already holds, then answering a storage question honestly. Where the source material is silent, this guide says so rather than filling the gap.
Adipose Tissue Is an Endocrine Organ, and Patients Sense a Connection
The first fair question is why fat, of all tissues, is being discussed in a gynecology office. The answer is legitimate science. Kershaw and Flier set out the case for adipose tissue as an endocrine organ in 2004, and Coelho and colleagues reviewed the biochemistry of adipose tissue in 2013, covering leptin and adiponectin.
That biology matters to a specialty managing hormonal change across a lifespan, and it is also where patient reasoning goes wrong. What the tissue secretes in the body says nothing about what isolated cells might do after collection, processing, and years of frozen storage. No adipose-derived product is FDA approved for any gynecologic indication.
Patients who have read the consumer piece on adipose tissue banking for women’s hormones and aging arrive with the endocrine framing in hand. What they lack is the regulatory picture that has to follow it.
What Decides Whether It Is Tissue or a Drug
Human cells, tissues, and cellular and tissue-based products fall under 21 CFR Part 1271. A product meeting all four criteria in section 1271.10(a) is regulated solely as a 361 HCT/P. Miss one, and it becomes a 351 product, a biological drug requiring an IND before human study and a BLA before marketing.
Physicians often assume autologous collection settles the analysis. It does not. All four criteria must hold at once, and the table shows where a gynecologic offering fails, as written at 21 CFR 1271.10(a).
| Criterion | What the regulation requires | Where a gynecologic offering is exposed |
|---|---|---|
| Minimal manipulation | Processing must not alter the relevant biological characteristics of cells, or the original relevant characteristics of structural tissue | Enzymatic digestion to isolate the stromal vascular fraction |
| Homologous use only | Intended use is judged by labeling, advertising, and other indications of objective intent | Advertising for a reproductive or hormonal purpose states a non-structural use |
| No prohibited combination | No combination with another article except water, crystalloids, or a sterilizing, preserving, or storage agent | Carriers or other actives combined with the product |
| Systemic effect and metabolic dependence | No systemic effect and no dependence on living cell metabolism, unless the use is autologous, in a close blood relative, or reproductive | Autologous collection satisfies this one, so practices assume the rest follows |
Criterion four repays a close reading, because it names reproductive use. That clause describes one condition under which a product with a systemic effect can still sit inside the tissue framework. It is not permission to advertise a reproductive service, and it does not excuse a product from minimal manipulation or homologous use. Clearing the fourth criterion while failing the first still yields a 351 drug.
What Patients Bring In From Advertising
Most of these conversations begin with an advertisement rather than a journal. The marketing language reaching women’s health patients includes ovarian rejuvenation, vaginal rejuvenation, and fertility claims. Those are advertising terms, not approved indications, and no adipose-derived product is FDA approved for any of them.
FDA’s consumer alert on regenerative medicine products states that blood-forming stem cells from cord blood are the only approved stem cell products and that no exosome product is FDA approved. It lists conditions these products are not approved to address, from arthritis to Alzheimer’s. The absence of a gynecologic condition from that list is not an endorsement of one.
The FTC layer applies at the same time. Its Health Products Compliance Guidance, published in December 2022, covers express and implied claims, the competent and reliable scientific evidence standard, clear and conspicuous disclosures, and endorsements. A patient video describing her symptoms is the advertiser’s own claim to substantiate. Knowing what patients believe before they sit down is half the visit.
Stem Cell Banking Pregnancy Questions: The Honest Answer on Timing
Among stem cell banking pregnancy questions, the most common is simply when. Should she bank before trying to conceive, during pregnancy, after delivery, or once she is finished having children?
No verified guidance on banking during or around pregnancy appears in the source material behind this article, and inventing one would be worse than admitting the gap. Timing belongs to the patient’s own physician, who knows her history, her plans, and the procedure under discussion.
Two things can be said without speculation. Collection happens during a procedure, so this is a surgical and obstetric judgment before it is a storage judgment. And banking connects the patient to no treatment pathway at any point on that timeline, so nothing about the calendar justifies rushing.
What Actually Affects What Gets Stored
Once the regulatory picture is clear, the questions turn practical. Does my weight matter, and am I too old for this to be worthwhile? Published banking-side data speak to both, usually against patient intuition.
| Patient question | What the published data report |
|---|---|
| Does a higher BMI mean more cells? | Aust and colleagues reported a mean cell yield from lipoaspirate of 404,000 plus or minus 206,000 cells per milliliter across 18 donors, with a significant negative correlation with BMI and none with age |
| Does donor age change the stored cells? | Devitt and colleagues, examining stored adipose tissue across 2 to 1159 days from donors aged 26 to 62, found that patient age did not significantly affect isolation, viability, or growth, with mesenchymal markers maintained throughout |
None of that says whether stored cells would ever be clinically useful. It describes what comes out of the tissue, which is the only question banking is positioned to answer.
Where State Law Leaves Gynecologic Use
State law adds a second layer, and it surprises physicians who have read only the federal rules. Florida is the clearest example. Its statute permits non-FDA-approved stem cell therapy only within the physician’s scope of practice and only where the use relates to orthopedics, wound care, or pain management. Gynecologic use is not on that list, so it sits outside what Florida authorizes.
Other states drew the line differently. Georgia’s law, effective July 1, 2026, carries no specialty limitation, and Tennessee’s law, effective the same day, had an orthopedics, wound care, and pain management limit removed by amendment before passage.
None of that governs storage, because storage is not therapy. It governs what a physician could do downstream, and a gynecologic indication is exactly where a specialty limitation bites first.
OB-GYN Adipose Banking in Daily Practice
Banking is the narrow and defensible activity here. Tissue is collected during a procedure the patient is already having, sent to a laboratory, and stored. No claim about a condition is attached.
Save My Fat is a connector rather than a provider, and it does not collect, process, store, or treat. Practices evaluating the model usually begin with how the provider network is structured, and guidance on introducing banking to patients is worth reading before the first consultation.
The whole conversation fits into a few sentences. Nothing is FDA approved for any gynecologic indication. Storage is storage. Eligibility and access cannot be guaranteed. Any future use would depend on FDA regulatory status, physician judgment, and whichever pathways exist at that time.
Frequently Asked Questions
What questions are OB-GYN patients commonly asking about adipose tissue banking?
Most ask whether it is FDA approved, whether it will help with hormonal changes, what it costs, when to do it relative to pregnancy, and how long tissue can be stored. The honest answers are that no adipose-derived product is approved for any gynecologic indication and that banking is storage rather than care.
Is there a connection between pregnancy planning and the timing of tissue banking?
No verified guidance on banking during or around pregnancy appears in the source material for this article, so the responsible answer is that timing belongs to the patient’s own physician. Collection happens during a procedure, which makes it a surgical and obstetric decision first. Banking creates no treatment pathway, so no clock is pushing it.
How does the patient-facing women’s health article differ from what OB-GYN physicians need to know?
The consumer article explains why adipose tissue is metabolically interesting and what banking involves. The clinician version adds what patients do not see: the four criteria at 21 CFR 1271.10(a), the 361 versus 351 line, FTC substantiation standards, and the state statutes limiting which specialties may use these products.
What compliance considerations are specific to discussing banking with OB-GYN patients?
Advertising is read as evidence of intended use, so a reproductive or hormonal purpose stated anywhere in practice materials can defeat homologous use. Testimonials count as the practice’s own claims. Keep the conversation on collection, processing, and storage, state plainly that nothing is approved for gynecologic use, and document it.
What should an OB-GYN practice tell patients about realistic expectations?
Tell them banking preserves tissue and nothing more. It does not reserve a place in a study, create access to any product, or predict what will exist years from now. Individual results may vary and outcomes cannot be predicted. Any future use would depend on FDA regulatory status and physician guidance.
Is any adipose-derived product FDA approved for a gynecologic indication?
No. FDA’s consumer alert states that blood-forming stem cells from cord blood are the only approved stem cell products and that no exosome product is approved. Nothing derived from adipose tissue is approved for any gynecologic, reproductive, or hormonal use, and marketing suggesting otherwise describes an unapproved product.
Key Takeaways
The value an OB-GYN adds here is accuracy, not enthusiasm. Adipose tissue is an endocrine organ, which is why patients intuit a link to their hormonal health, but what the tissue secretes in the body proves nothing about isolated cells after processing and storage. No adipose-derived product is FDA approved for any gynecologic, reproductive, or hormonal indication, and terms like ovarian rejuvenation are advertising language rather than approved uses.
The federal line runs through the four criteria at 21 CFR 1271.10(a), where autologous collection satisfies only the fourth. Florida authorizes non-FDA-approved stem cell therapy only for orthopedics, wound care, and pain management, leaving gynecologic use outside it. On timing around pregnancy, the question belongs to the treating physician. Banking is storage, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Practices weighing adipose tissue banking for potential future use can review current options and pricing, and referral questions can go to the Save My Fat team.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including obstetrics and gynecology input is required before publication. Please consult your obstetrician or gynecologist before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: the physician resource center.
